The safety profile of adjunctive Zonegran (zonisamide), from Eisai, in paediatric patients with partial Epilepsy is confirmed by pooled data...
This guide has therefore been prepared with the important objective of providing healthcare professionals with reference information on both the science and regulation underpinning the use of biosimilars.
Areas covered: Herein, the authors discuss the pharmacology, clinical efficacy and the adverse effects of zonisamide. The article is derived from clinical trial data, long-term studies, meta-analyses, review articles, text books...
This guideline is restricted to GI endoscopy but we cover elective and acute or emergency procedures.
Preliminary results from a new Phase III study of Zonegran (zonisamide) from Eisai, shows that it is more effective than...
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support.
Zonisamide is indicated as: • monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy (see section 5.1); • adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.
This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care.